Dr Klaus Metzeler discusses the current technologies for detecting measurable residual disease (MRD) in acute myeloid leukaemia (AML) at the upcoming AMP 2023 webinar. Dr Metzeler's comprehensive data, utilising OGT’s SureSeq™ Myeloid MRD Panel, highlights its remarkable attributes, including exceptional coverage uniformity, a 100% concordance rate with a local NGS panel, and the precise identification of clinically significant variants such as FLT3-ITD mutations.

Explore the forefront of technological advancements in AML research with Dr Metzeler as he unveils the promising insights garnered from OGT’s SureSeq™ Myeloid MRD Panel, providing a detailed examination of its capabilities in enhancing our understanding of AML and its genetic complexities. Don't miss the opportunity to gain valuable insights and updates on the latest advancements in the field.